GlassScriptPhysician profile
Msonthi B Levine
NPI 1962430413
$9,765.54
in general payments reported to CMS, 2019-2025
59 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $989 · 2021: $1,622 · 2022: $1,309 · 2023: $1,186 · 2024: $1,558 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,211.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,122.38 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $928.45 | 2020-2025 | |
| Novo Nordisk INC | $711.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $637.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $554.56 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $541.48 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $377.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $367.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.02 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $267.06 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $253.98 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.78 | 2020-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $159.53 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $149.59 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Msonthi Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.